Health Care
(E66Z)
990 on File
CASCADE HEMOPHILIA CONSORTIUM
Financial strength (30%)
82/100
Reliability (20%)
55/100
Effectiveness (25%)
51/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2024
$26.8M
Total Revenue
$13.7M
Total Expenses
$84.9M
Net Assets
N/A
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
94.3%
Fundraising Efficiency
N/A
Operating Reserve
74.25x
Liability-to-Asset
15.8%
Revenue Diversification
10.0%
Executive Compensation
$290K
Compared with Peers
FY 2024
Compared with 2,013 similar organizations
(United States, Health Care, $10M–$100M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
94.3% | 84.6% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
74.3 mo | 6.8 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
15.8% | 35.3% |
P10P90
|
Above median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
10.0% | 92.5% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
5.2% | 7.3% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
19.1% | 7.7% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
48.9% | 1.0% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $26.8M | $13.7M | $84.9M | 94.3% | — |
| 2023 | $25.5M | $11.5M | $71.7M | 99.3% | — |
| 2022 | $19.8M | $9.8M | $57.7M | 96.0% | — |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.